Until recently, IgE-activated mast cells have been regarded merely as effector cells of adaptive immune responses, involved in allergic reactions and mucosal immunity to parasites. Herein we report that murine dermal mast cells, activated by local administration of a creme containing the synthetic TLR7 ligand imiquimod, are essential to initiate an early inflammatory reaction. The mast cell-derived cytokines TNF-α and IL-1β play an important role in this process. Furthermore, TLR7 activated mast cells are also able to promote the emigration of Langerhans cells, which partly depends on the expression of mast cell-derived IL-1β. We have previously shown that TLR7 ligation enhances transcutaneous immunization evoked by topical application of vaccine antigens to the skin, a procedure which directly targets skinresident antigen presenting cells. Consequently, we now demonstrate here that the capacity to mount a peptide-specific cytotoxic T lymphocyte response following transcutaneous immunization employing imiquimod as adjuvant is severely impaired in mast cell-deficient mice. Thus, these findings demonstrate the potent versability of alternatively activated mast cells at the interface of innate and adaptive immunity.
Introduction
IgE-dependent reactions including dysregulated allergic responses to environmental antigens and mucosal immunity to some extracellular parasites were believed to be the hallmarks of mast cell immunology for several decades .
We know by now that mast cells, predominantly localized at the interface between host and environment (i. e. skin and mucosal surfaces), are in addition able to perceive a variety of allergens and invading pathogens. Based on two groundbreaking publications using murine models of acute bacterial infection, mast cells were found to be critical effectors of innate immunity. In these studies, mast celldeficient mice were highly susceptible to induced septic peritonitis 1 and Klebsiella pneumoniae instillation 2 . In these settings, the unique ability of mast cells to secrete preformed TNF-α within minutes following IgE-independent stimulation enables the host to mount an early and protective neutrophil response to bacterial challenge.
Evidence further accumulates that mast cells are implicated in host defence against an still increasing range of clinically relevant bacterial infections [3] [4] [5] . Furthermore, mast cells are also thought to participate in response to viruses, but this is less understood and deserves further research 5, 6 . With respect to IgE-independent activation, both rodent and murine mast cells were found to express a variety of Tolllike receptors, some of which are only expressed on certain mast cell subsets [5] [6] [7] .
However, several murine in vivo models clearly showed the importance of TLRmediated mast cell activation, e.g. for the clearance of enterobacterial infection by triggering TLR4 8 and for the recruitment of CD8 + T cells into the peritoneal cavity following ligation of TLR3 with poly(I:C), which mimics viral dsRNA 9 .
It is also increasingly being appreciated that mast cells are able to finely control the magnitude of the secretory response following activation 10 . Thus, IgE-independent
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It was also suggested that mast cells can directly promote the development of adaptive immunity, as it was shown that they can trigger the migration of antigen presenting cells in several murine models [12] [13] [14] .
Besides their potential influence on antigen presenting cells, mast cells were also shown to directly promote T cell proliferation and cytokine secretion. This requires IgE-mediated mast cell activation, TNF-α produced by mast cells and T cells and mast cell expression of OX40L, triggering the costimulatory molecule OX40 on T cells 15, 16 . This ability of mast cells seems suitable to enhance the recall reaction of primed T cells locally upon re-encountering the antigen.
However, heretofore it was not yet clear whether mast cells are associated with the development or magnitude of an adaptive T cell response.
We previously reported that the simple epicutaneous application of a creme containing a CTL epitop in combination with the synthetic TLR7 ligand imiquimod leads to the transport of applied peptide to local lymph nodes (LN). Consequently, this method is highly effective to mount a full-blown immune response against the target peptide 17 . Local epicutaneous treatment with imiquimod as an adjuvant induces both an inflammatory response as well as the migration of Langerhans cells (LC) out of the epidermis 18 . LC, the DC of the epidermis, are able to cross-present exogenous antigen on MHC class I molecules to CD8 + cytotoxic T cells in skindraining lymph nodes [19] [20] [21] .
Herein we show that both early cutaneous inflammation and migration of LC are promoted by dermal mast cells activated through TLR7, and we identify mast cellderived TNF-α and IL-1 as essential mediators. Most importantly, dermal mast cells LN cell suspensions were generated by collagenase digestion as described previously 27 and immunostained using APC-conjugated anti-MHCII, PE-conjugated 28 . Single cell suspensions from ear skin of 4get mice were obtained as described 29 . In brief, ears were divided into dorsal and ventral halves and both halves were incubated (dermis down) in MEM containing 0.5 mg/ml Liberase CI . In brief, DC were differentiated with GM-CSF for 6 days with medium replacements on days 2 and 4. On day 6, the immature DC were activated with poly-(I:C) (Amersham, Germany) for 18 hours.
Immunization with peptide-pulsed DC was done according to 32 . Briefly, activated DC were loaded with SIINFEKL peptide and 1 x 10 6 DC were injected intraperitoneally into Kit W-sh/W-sh or the Kit +/+ control mice.
Transcutaneous immunization (TCI). TCI was according to the protocol established
by our group 17 . In brief, TCI was performed on two consecutive days by mixing of 100 µg of SIINFEKL peptide with 60 mg of pre-formulated imiquimod creme (Aldara; 3M Pharmaceuticals; this corresponds to 3 mg active agent) per mouse per application. TCI was applied onto the back of anesthetized mice (~10 cm 2 ), that had been shaved at least 2 days prior immunization. Two days after shaving and prior immunization the mice did not have skin irritation on their shaved back. 
Results

Mast cells initiate inflammation and promote emigration of LC following local treatment with imiquimod.
The expression of TLR7 mRNA in murine fetal skin-derived cultured mast cells (FSMC) was recently described, and we therefore hypothesized that dermal mast cells may contribute to the initiation of an inflammatory response following local treatment with imiquimod 7 . Due to the lack of appropriate antibodies, we were unable to stain TLR7 positive mast cells -or any other TLR7 expressing cell type-in tissues. Therefore, we used RT-PCR to investigate TLR7 mRNA expression in BMMC and dermal mast cells, the latter isolated as c-Kit + GFP + cells from the skin of 4get mice 28 . As depicted in Fig. 1A , BMMC constitutively express low but detectable levels of TLR7 mRNA, which is in accordance with published data 7 . In BMMC, TLR7
mRNA expression increases upon incubation with the TLR7 ligand imiquimod in vitro.
Dermal mast cells freshly isolated from untreated mice also express TLR7 mRNA. In dermal mast cells isolated from mice which were topically treated once daily with imiquimod on two consecutive days, TLR7 mRNA expression level remains unaffected (Fig. 1A) . ligation. Reconstitution with TLR7-deficient BMMC leads to an inflammatory reaction with delayed kinetics, even slower to the one observed in mast cell-deficient mice.
It was also recently reported that treatment with imiquimod induces the migration of LC, although murine LC themselves lack expression of TLR7 18, 33 . Therefore, we assumed that dermal mast cells, activated via TLR7, might promote the emigration of LC. In order to investigate this idea, epidermal sheets from animals, previously treated over 4 days once daily with imiquimod or vehicle, were stained for MHC class II positive LC (Fig. 1C) . In untreated skin, we observed no significant differences in LC numbers between mast cell-deficient and wild type mice, which is in accordance with previous reports [12] [13] [14] (and data not shown). Following treatment with imiquimod, the migration of LC in Kit W-sh/W-sh mice is reduced by 50 % compared with wild type mice. Migration could be efficiently restored in mast cell-deficient mice upon transfer of BMMC derived from wild type but not from TLR7-deficient animals. Hence, dermal mast cells are able to act as a sensor for TLR7 ligand, thereby boosting both early local inflammation and migration of LC. It should be noted that in contrast to the ear swelling response, the numbers of emigrating LC under the specific conditions shown in Fig. 1C did not approximate to each other over time, even after daily treatment with imiquimod for up to 7 days (Fig. 1D) .
Mast cell-derived cytokines contribute to inflammation and migration of LC.
Activated mast cells are a rich source of proinflammatory cytokines, which may promote both inflammation (i. e. ear swelling) and emigration of LC in imiquimod-treated skin. In order to pursue this hypothesis further, we analyzed the mRNA expression pattern of important proinflammatory mediators in the ears of both mast cell-deficient and wild type mice following treatment with imiquimod. As displayed in Fig. 2A , expression of mRNAs encoding TNF-α and IL-1β is increased in the ears of wild type mice 2 h after application of the creme, whereas no augmentation of mRNA production is detectable in either vehicle treated controls or in Kit W-sh/W-sh mice. We followed expression of IL-1β and TNF-α mRNAs for up to 8 h after treatment with imiquimod. In wild type mice, sustained expression of both mRNAs was observed. In mast cell-deficient mice, no increase in TNF-α mRNA production was measureable, but IL-1β mRNA expression started 4 h after application of imiquimod (data not shown).
To further dissect the possible role(s) of mast cell-derived cytokines, we locally 2C ) is delayed by one day. This indicates that both mast cell-derived cytokines play a role in the fast onset of inflammation. However, only mast cell-derived IL-1, but not TNF-α, contributes significantly to the emigration of LC (Fig. 2D) . In order to rule out that these results are due to differences in engraftment efficiencies between mast cell-deficient mice reconstituted with BMMC derived from different knock out strains,
we assessed mast cell numbers in the ears 6 weeks after selective engraftment with mast cells in the ear pinnae. As shown in Table 1 (Fig. 3A) . This indicates that mast cells and mast cell-derived TNF-α are critical initiators of LN hypertrophy, which has previously been reported for LN hypertrophy in response to infection with E. coli 34 .
To follow the immigration of LC to the LN, we stained Langerin positive cells, i. e. LC, in auricular LN cell suspensions following application of imiquimod to the ears. As depicted in Fig. 3B , numbers of Langerin positive cells in LN increase more than 3-fold in wild-type mice on day 3 following daily treatment with imiquimod, whereas the influx is significantly reduced in Kit W-sh/W-sh mice. In pilot experiments we found that numbers of LC in LN increased between d2 and d3 after daily treatment with imiquimod and then rapidly declined to baseline levels around day 7 (data not shown). In accordance with our data on the emigration of LC out of the epidermis (Fig. 1C and Fig. 2D (Fig. 3B) . However, although the number of LC immigrating into the draining LN is severely reduced in mast cell-deficient animals, LC are phenotypically 5A, peptide-specific CTL are detected in peripheral blood using tetramer staining on day 6, after animals were creamed twice on days 0 and 1 of the experiment. In wild type mice immunized using peptide in combination with imiquimod, a significant
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For Our work presented herein describes an important role for TLR7-activated dermal mast cells with respect to the early onset of inflammatory skin reaction, emigration of LC and the magnitude of CTL response, the latter most likely by promoting the migration of peptide-loaded LC to the local lymph nodes 17 . Hence, mast cells together with DC represent the hinge between innate and adaptive immunity, able to boost the development of a specific immune reaction.
Impaired migration of epidermal LC and attenuated contact hypersensitivity following topical hapten exposure was also shown in mast cell-deficient mice and animals lacking either IgE or FcεRI 12 . Furthermore, in a modell for passive cutaneous anaphylaxis, it was reported that local IgE/antigen-mediated mast cell activation provides a strong signal for the migration of LC to the draining lymph nodes. This was partly dependent on histamine acting on H2 receptors, but it was also noted that local administration of histamine alone did not induce LC migration, indicating that other mast cell-derived products must play a role in this process 13 . Very recently, it
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48-72 h after hapten application. More importantly, 6 days after hapten application, identical levels of T cell proliferation induced by restimulation with hapten ex vivo was measured in wild-type, mast cell-or TNF-α-deficient mice. Thus, in the study by Suto et al.
14 , mast cells obviously accelerate the migration of LC to the draining LN but are not required to promote an adaptive T cell response. This is in contrast to our present study where the migration of LC following application of imiquimod is not only delayed but also remains reduced at later time points, which correlates with an severely impaired CTL response in mast cell-deficient mice.
A recent study examined the mechanisms of LC migration and LN hypertrophy in response to Gram-positive Staphylococcus aureus peptidoglycan (PGN) 37 . In agreement with our data, PGN-induced LC migration and LN hypertrophy were both profoundly mast cell-dependent. However, IgE/antigen-induced LC migration was completely TNF-α-dependent while PGN-induced LC migration was partially independent of TNF-α. Furthermore, this study also revealed that LN hypertrophy following IgE crosslinking requires TNF-α while PGN-induced LN hypertrophy is TNF-α -independent. As a conclusion we hypothesize that the mechanisms of mast celldependent phenomena, e. g. role of TNF-α in LC migration, are deeply influenced by the mode of mast cell activation. This hypothesis is corroborated by the finding that mediator production by mast cells differs in response to various stimuli, e.g. IgE crosslink versus stimulation with PGN 37 or even among different TLR activators 7 .
In addition it should be noted that different stimuli can trigger different cell types in situ. In our modell, obviously other cell types in the skin are also able to recognize TLR7 ligands and to induce an inflammatory reaction, albeit with slower kinetics (see Fig. 1B ). Likely candidates for this phenomenon are dermal DC and a recently described population of plasmacytoid DC-like cells 38, 39 . The latter accumulate in the skin several days after daily treatment with imiquimod and are believed to promote inflammation by producing type I interferons 39 . However, our results show that mast cells are necessary to induce an early inflammatory skin response.
At present, transcutaneous immunization protocols appear promising, as they are non-invasive, easy to perform and cost-effective 40, 41 . An understanding of the underlying mechanisms may help to develop such strategies more specifically in the future.
In addition to the use of imiquimod as an adjuvant, antiviral and antitumor effects of this drug have also been described 39, [42] [43] [44] . Therefore, it is tempting to speculate that mast cells might also be critically involved in these reactions, which is currently under investigation. For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From
